

# SmartPA Criteria Proposal

<b>Drug/Drug Class:</b>	Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables PDL Edit
<b>First Implementation Date:</b>	October 6, 2004
<b>Revised Date:</b>	April 6, 2023
<b>Prepared For:</b>	MO HealthNet
<b>Prepared By:</b>	MO HealthNet/Conduent
<b>Criteria Status:</b>	<input type="checkbox"/> Existing Criteria <input checked="" type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

## Executive Summary

**Purpose:** The MO HealthNet Pharmacy Program will implement a state-specific preferred drug list.

**Why Issue Selected:** The 5-HT3 receptor antagonists are indicated for the prevention and treatment of nausea and vomiting associated with chemotherapy and radiotherapy. Diclegis® (doxylamine/pyridoxine) is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Metoclopramide is indicated for diabetic gastroparesis and gastroesophageal reflux, as well as off-label use for treating nausea and vomiting associated with chemotherapy and radiation. Neurokinin-1 (NK1) receptor antagonists have indications that include prevention and treatment of nausea and vomiting associated with chemotherapy and radiotherapy and post-operative nausea and vomiting. The management of chemotherapy-induced nausea and vomiting is a critical aspect of treating cancer patients. The advent of agents within this therapeutic class was a significant breakthrough for the practice of oncology. However, because of the increased cost of these products, it is essential that therapy is appropriately monitored, and prudently utilized for the appropriate patient population.

Total program savings for the PDL classes will be regularly reviewed.

Program-Specific Information:	Preferred Agents	Non-Preferred Agents
	<ul style="list-style-type: none"> <li>• Aprepitant Caps</li> <li>• Metoclopramide Soln/Tabs</li> <li>• Ondansetron ODT/Soln/Tabs</li> </ul>	<ul style="list-style-type: none"> <li>• Akynzeo® Caps</li> <li>• Anzemet®</li> <li>• Bonjesta®</li> <li>• Diclegis®</li> <li>• Doxylamine/Pyridoxine</li> <li>• Emend® Caps/Pwd Packet</li> <li>• Gimoti®</li> <li>• Granisetron Tabs</li> <li>• Metoclopramide ODT</li> <li>• Reglan®</li> <li>• Sancuso®</li> <li>• Zofran® Tabs</li> </ul>

**Type of Criteria:**  Increased risk of ADE  Preferred Drug List

Appropriate Indications

Clinical Edit

Data Sources:  Only Administrative Databases

Databases + Prescriber-Supplied

## Setting & Population

- Drug class for review: Antiemetics, 5-HT3, NK1 and Other Select Non-Injectables
- Age range: All appropriate MO HealthNet participants

## Approval Criteria

- For aprepitant capsules: maximum quantity of 3 doses per chemotherapy course **OR**
- Failure to achieve desired therapeutic outcomes with a trial on 1 or more preferred agents:
  - Documented trial period for preferred agents **OR**
  - Documented ADE/ADR to preferred agents **AND**
- For Diclegis and Bonjesta: adequate therapeutic trial of doxylamine (trial defined as 60/90 days)
- **For Zuplenz: Clinical Consultant Review required for medical necessity of therapy**

## Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Lack of adequate trial on required preferred agents
- Claim exceeds maximum dosing limitations for the following:

Drug Description	Generic Equivalent	Max Dosing Limitations
<b>ANZEMET 100 MG</b>	<b>DOLASETRON</b>	<b>1 tablet per day</b>
ANZEMET 50 MG	DOLASETRON	1 tablet per day
GRANISETRON 1 MG	GRANISETRON	2 tablets per day
<b>ZOFRAN 24 MG</b>	<b>ONDANSETRON</b>	<b>1 tablet per day</b>
<b>ZUPLENZ 4 MG</b>	<b>ONDANSETRON</b>	<b>3 films per day</b>
<b>ZUPLENZ 8 MG</b>	<b>ONDANSETRON</b>	<b>3 films per day</b>

## Required Documentation

Laboratory Results:   
MedWatch Form:

Progress Notes:   
Other:

## Disposition of Edit

Denial: Exception Code "0160" (Preferred Drug List)  
Rule Type: PDL

## Default Approval Period

6 months

## References

- Evidence-Based Medicine and Fiscal Analysis: "Antiemetic Agents – Therapeutic Class Review", Conduent Business Services, L.L.C., Richmond, VA; November 2021.

*SmartPA PDL Proposal Form*

© 2023 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.  
Other company trademarks are also acknowledged.

- Evidence-Based Medicine Analysis: “Antiemetics - 5-HT3, THC Derivatives, NK1 & Other Agents”, UMKC-DIC; September 2022.
- USPDI, Micromedex; 2022.
- Facts and Comparisons eAnswers (online); 2022 Clinical Drug Information, LLC.

DRAFT